Drug Profile
Omeprazole - AstraZeneca/Mitsubishi Tanabe Pharma Corporation
Alternative Names: Antra; Belmazol; Losec; Mopral; Nuclosina; Omepral; Omeprazole magnesium; Omeprazon; Prilosec; UlzolLatest Information Update: 05 Nov 2023
Price :
$50
*
At a glance
- Originator AstraZeneca
- Developer AstraZeneca; Hassle Lakemedel; Mitsubishi Tanabe Pharma Corporation
- Class 2 pyridinylmethylsulfinylbenzimidazoles; Antiulcers; Gastric antisecretories; Small molecules
- Mechanism of Action Proton pump inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Marketed Duodenal ulcer; Dyspepsia; Gastric ulcer; Gastritis; Gastro-oesophageal reflux; Helicobacter infections; Peptic ulcer; Zollinger-Ellison syndrome
Most Recent Events
- 27 Jul 2022 Lacer has been acquired by Italfarmaco
- 01 Oct 2019 Cheplapharm Arzneimittel acquires the global commercial rights, excluding China, Japan, USA and Mexico, for omeprazole and associated brands from AstraZeneca
- 13 Jul 2018 Valeant Pharmaceuticals International is now called Bausch Health Companies